Acorn Bioventures Divests Cyclacel Pharma Stake

TL;DR

**Acorn Bioventures just dumped their Cyclacel Pharma shares, watch out!**

AI Summary

Acorn Bioventures, L.P. filed an amended Schedule 13G/A on February 7, 2024, indicating a change in their beneficial ownership of Cyclacel Pharmaceuticals, Inc. common stock as of December 31, 2023. While they previously held a significant stake, this filing shows they now report 0 shares with sole voting power and 0 shares with shared voting power, suggesting a complete divestment or a substantial reduction below the reporting threshold. This matters to investors because a major institutional investor has either sold off their entire position or significantly reduced it, which could signal a lack of confidence in Cyclacel's future prospects.

Why It Matters

This filing indicates a significant institutional investor, Acorn Bioventures, L.P., has likely sold off its entire position in Cyclacel Pharmaceuticals, Inc., which could be interpreted negatively by the market.

Risk Assessment

Risk Level: high — A major institutional investor exiting their position can signal underlying issues or a lack of future confidence, increasing investment risk.

Analyst Insight

A smart investor would investigate the reasons behind Acorn Bioventures' complete divestment from Cyclacel Pharmaceuticals, Inc. and consider if this signals fundamental issues before making any investment decisions.

Key Numbers

• 0 — Sole Voting Power Shares (Acorn Bioventures, L.P. now holds 0 shares with sole voting power in Cyclacel Pharmaceuticals, Inc.)
• 0 — Shared Voting Power Shares (Acorn Bioventures, L.P. now holds 0 shares with shared voting power in Cyclacel Pharmaceuticals, Inc.)
• December 31, 2023 — Date of Event (The date of the event requiring this filing, indicating the ownership status at year-end.)

Key Players & Entities

• Acorn Bioventures, L.P. (company) — the reporting person who filed the SC 13G/A
• Cyclacel Pharmaceuticals, Inc. (company) — the issuer whose securities are being reported
• Delaware (company) — place of organization for Acorn Bioventures, L.P.
• $0.001 (dollar_amount) — par value per share of Cyclacel Pharmaceuticals, Inc. common stock

Forward-Looking Statements

• Cyclacel Pharmaceuticals, Inc.'s stock price may experience downward pressure due to the perceived lack of institutional confidence. (Cyclacel Pharmaceuticals, Inc.) — medium confidence, target: Q1 2024
• Other institutional investors might review their positions in Cyclacel Pharmaceuticals, Inc. following Acorn Bioventures' divestment. (institutional investors) — medium confidence, target: Q2 2024

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securitie

Filing Documents

• p24-0477sc13ga.htm (SC 13G/A) — 75KB
• 0000902664-24-001230.txt ( ) — 77KB

(a)

Item 1(a). Name of Issuer. Cyclacel Pharmaceuticals, Inc. (the " Issuer ")

(b)

Item 1(b). Address of Issuer's Principal Executive Offices. 200 Connell Drive, Suite 1500 Berkeley Heights, New Jersey 07922

(a)

Item 2(a). Name of Person Filing. This statement is filed by: (i) Acorn Bioventures, L.P. (" Acorn "); (ii) Acorn Capital Advisors GP, LLC (" Acorn GP "), which is the sole general partner of Acorn; and (iii) Anders Hove (" Hove "), who is the manager of Acorn GP. The foregoing persons are hereinafter sometimes collectively referred to as the " Reporting Persons ." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.

(b)

Item 2(b). Address of Principal Business Office. The address of the principal business office of each of the Reporting Persons is 420 Lexington Avenue, Suite 2626, New York, New York 10170.

(c)

Item 2(c). Place of Organization. Acorn is a Delaware limited partnership. Acorn GP is a Delaware limited liability company. Hove is a citizen of the United States of America.

(d)

Item 2(d). Title of Class of Securities. Common stock, $0.001 par value per share (the " Common Stock ")

(e)

Item 2(e). CUSIP Number. 23254L603 CUSIP No. 23254L603 13G/A Page 6 of 8 Pages Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a: (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); (g) o A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813); (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. The percentage of class as of December 31, 2023 was calculated based on 1,019,310 shares of Common Stock, as reported in the Issuer's Prospectus filed pursuant to Rule 424(b)(5) with the Commission on December 26, 2023, after giving effect to the completion of the offering as described therein, and assumes the exercise o

View Full Filing

View this SC 13G/A filing on SEC EDGAR